Page 3 - Access Consortium News Today

Vaccines modified to beat new Covid variants will be fast-tracked Research has suggested the rate of decline in Covid-19 infections in England has slowed Updated The video will auto-play soon8Cancel Play now Never miss another Leicestershire story by signing up to our free email updatesInvalid EmailSomething went wrong, please try again later. Sign up When you subscribe we will use the information you provide to send you these newsletters. Sometimes they’ll include recommendations for other r...

NEW Covid vaccines to fight variants will be fast tracked for approval, the UK regulator has said.The approach will follow a similar process as the an

The regulatory approach to new vaccines will be similar to the modified flu jab, which changes every year.

The regulatory approach to new vaccines will be similar to the modified flu shot, which changes every year.

Read more about UK regulator to fast-track vaccine updates to combat new Covid variants on Business Standard. Modified vaccines to protect against new variants of coronavirus can be fast-tracked through the approval system, the UKs independent medicines regulator said on Thursday.

Manufacturers will not need to conduct whole new clinical trials when they adapt their vaccines for newer coronavirus strains

Why governments need to rethink their regulatory framework in 2021 - Magazine Article - PharmaTimes

UK was ill-prepared for the transition of regulation from the EU and still does not have the infrastructure in place to manage new trade relationships UK...

UK COVID-19 vaccines delivery plan Updated 13 January 2021 © Crown copyright 2021 This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk. Where we have identified any third party copyright information you will need to obta...

In the fall of 2016, Alnylam Pharmaceuticals was looking to expand. The Cambridge, Massachusetts–based company had therapies based on RNA interference (RNAi) technology in late-stage clinical testing for a handful of rare diseases, and wanted to establish a presence in Europe to better serve patients there. By the end of the following year, the company had opened offices in Maidenhead, UK; Zug, Switzerland; and Amsterdam, the Netherlands, to serve as its three European hubs. Scouting for new ...